Q-omics provides the consensus-scored SNTN profile across patient tissues and cancer cell-line models. SNTN expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SNTN is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, SNTN RNA expression shows 12,953 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight BRCA, LUSC, and UCEC as cancer lineages where SNTN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNTN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNTN survival associations across molecular data types. SNTN RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNTN RNA expression–survival associations across cancer types. High SNTN expression shows unfavorable associations in DLBC, PCPG, HNSC and SCLC, but favorable associations in BRCA and COAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for SNTN RNA expression.
This table summarizes SNTN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SNTN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNTN shows lower tumor expression in LUSC, LUAD, KICH and KIRC and higher tumor expression in BRCA and COAD. The LUSC box plot shows higher SNTN RNA expression in normal versus tumor tissue (log2 FC = −2.682, t-test p < 0.001).
This table shows molecular features associated with SNTN in patient tissues and cancer cell lines. In patient samples, SNTN shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNTN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
